178 related articles for article (PubMed ID: 38411882)
21. The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.
Hou L; Qiu M; Chen M; Li F; Li J; Deng S; Yang Y; Du Z; Yang H
Gland Surg; 2021 Jun; 10(6):1889-1898. PubMed ID: 34268073
[TBL] [Abstract][Full Text] [Related]
22. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis.
Zhang X; Xing C; Guan W; Chen L; Guo K; Yu A; Xie K
Cancer Cell Int; 2020; 20():169. PubMed ID: 32467665
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
[TBL] [Abstract][Full Text] [Related]
26. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
27. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
[TBL] [Abstract][Full Text] [Related]
28. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
[TBL] [Abstract][Full Text] [Related]
29. Low RAI2 expression is a marker of poor prognosis in breast cancer.
Nishikawa S; Uemoto Y; Kim TS; Hisada T; Kondo N; Wanifuchi-Endo Y; Fujita T; Asano T; Katagiri Y; Terada M; Kato A; Dong Y; Sugiura H; Okuda K; Kato H; Osaga S; Takahashi S; Toyama T
Breast Cancer Res Treat; 2021 May; 187(1):81-93. PubMed ID: 33782811
[TBL] [Abstract][Full Text] [Related]
30. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
31. Predictive biological factors for late survival in patients with HER2-positive breast cancer.
Kang YJ; Oh SJ; Bae SY; Kim EK; Lee YJ; Park EH; Jeong J; Park HK; Suh YJ; Kim YS
Sci Rep; 2023 Jul; 13(1):11008. PubMed ID: 37420033
[TBL] [Abstract][Full Text] [Related]
32. Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study.
Gentile D; Sagona A; Spoto R; Franceschini D; Vaccari S; Vinci V; Biondi E; Scardina L; Tinterri C
Eur J Breast Health; 2022 Oct; 18(4):315-322. PubMed ID: 36248756
[TBL] [Abstract][Full Text] [Related]
33. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer.
Hu XY; Ling ZN; Hong LL; Yu QM; Li P; Ling ZQ
J Clin Lab Anal; 2021 Sep; 35(9):e23936. PubMed ID: 34390026
[TBL] [Abstract][Full Text] [Related]
34. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer.
Shi Q; Wang J; Ai X; Xuhong J; Ma D; Zhang Y; Qi X; Jiang J
Gland Surg; 2021 Jul; 10(7):2255-2265. PubMed ID: 34422596
[TBL] [Abstract][Full Text] [Related]
36. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
37. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
38. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count.
Dhakal HP; Bassarova A; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Giercksky KE; Nesland JM
Histol Histopathol; 2009 Aug; 24(8):1049-59. PubMed ID: 19554512
[TBL] [Abstract][Full Text] [Related]
39. Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers.
Suh EJ; Kabir MH; Kang UB; Lee JW; Yu J; Noh DY; Lee C
Exp Mol Med; 2012 Jan; 44(1):36-44. PubMed ID: 22024541
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients.
Cabinakova M; Mikulova V; Malickova K; Vrana D; Pavlista D; Petruzelka L; Zima T; Tesarova P
Neoplasma; 2015; 62(2):259-68. PubMed ID: 25591591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
